What we do Vivimed Labs Limited manufactures specialty chemicals for personal care and pharmaceuticals, including APIs and formulations, serving global health, beauty, and contract manufacturing sectors. |
Founded in 1,988 |
Market share Strong presence in specialty chemicals and pharmaceutical API manufacturing, with global subsidiaries enhancing market reach. |
Problem solved Provides active ingredients and finished dosage products to address needs in personal care, pharmaceuticals, and contract manufacturing. |
Top clients or who we serve B2B focus serving personal care product manufacturers, pharmaceutical companies, and contract research clients globally including Europe, USA, and CIS markets. |
Key management Santosh Varalwar (Managing Director); Manohar Rao Varalwar (Chairman cum Whole-Time Director); Sandeep Varalwar (Whole-Time Director). |
Our journey and innovations Since 1988, expanded from NSAIDs to specialty chemicals and pharma; acquired global companies; developed anticancer and antimicrobial molecules; expanded R&D and manufacturing facilities. |
Where we operate India, United Kingdom, United States, Spain, Hungary, Mexico, Ukraine, Russia, Europe, CIS countries. |
Top products or what we offer Specialty chemicals like Triclosan substitutes, sunscreens, anti-dandruff agents; APIs for cancer, tuberculosis, antidiabetics; finished dosage pharmaceutical products. |
Top brands Vintox (anti-oxidant and anti-cancer molecule); MBB (hair care product); various API and formulation brands in pain management and ophthalmology. |
Raw materials needed Raw materials for specialty chemicals and APIs including organic compounds and chemical intermediates. |
Raw materials supplier Supplier details not specified; global sourcing to support diverse product portfolio. |
Recurring vs cyclical contribution Revenue mostly cyclical due to pharma manufacturing contracts and specialty chemical sales tied to market demand. |
Our industry position Mid-sized player with growing global footprint; niche in specialty chemicals and pharmaceutical contract manufacturing. |
Financial highlights FY2025 consolidated revenue of Rs. 1206.4 million with EBITDA loss reduction; net loss Rs. (319.61) million showing improving profitability trajectory. |
Geographical revenue split Significant operations in India, Europe, USA, CIS regions; exports to developed markets including Canada and EU noted. |
Order book - |
Whats driving growth Global demand for generics, specialty chemicals innovation, acquisitions, expanding pharma product basket, and regulatory approvals in developed markets. |
Our future plans Expand API capacity, drive product innovation, strengthen parenteral R&D, and negotiate bank settlements for financial robustness. |
Our green promise - |
Our people and values Focus on skilled human resources, training, sports activities, ethical practices, and strong corporate governance. |
Key challenges ahead High debt levels, ongoing bank negotiations, audit qualifications, and market competition pose challenges. |
Interesting facts One of the few Indian companies with global specialty chemical and pharma manufacturing footprint including acquisitions in Europe and USA. |
Risks and strategy Negotiating loan settlements; focusing on internal controls, risk management policy, and business diversification to mitigate risks. |
